← Patent-cliff monitor small molecule RUBRACA RUCAPARIB CAMSYLATE
Loss of exclusivity August 2035 latest FDA-listed patent expiry
Company PHARMAAND GMBH
Drug detail Brand name RUBRACA Active ingredient RUCAPARIB CAMSYLATE Strength EQ 200MG BASE Dosage form TABLET Route ORAL Modality Small molecule FDA approval December 2016 Marketing status RX
Listed patents Patent Expires Type 10130636 August 2035 use U-2830 9987285 August 2035 product 8859562 August 2031 use U-2830 9045487 February 2031 substance, product 9861638 February 2031 use U-2273 8754072 February 2031 substance, product 10278974 February 2031 product 8143241 August 2027 use U-2830 8071579 August 2027 use U-2830
Regulatory exclusivity Code Expires I-982 December 2028
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.